American journal of respiratory and critical care medicine
Audio Summaries

Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP

Sep 23, 2026

This study investigates the efficacy of biologic treatments for severe asthma in patients with varying smoking statuses, aiming to determine whether smoking exposure affects treatment outcomes. The findings indicate that all groups, including current and ex-smokers, experienced significant improvements in asthma control and quality of life after one year of biologic therapy, challenging the prevailing reluctance to prescribe biologics to smokers. The authors advocate for further randomized controlled trials to better inform treatment guidelines for this population.

Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Sep 23, 2026

The authors aimed to evaluate the efficacy of inhaled treprostinil in slowing lung function decline and improving clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF) by analyzing combined results from the TETON-1 and TETON-2 trials. The study found that treprostinil significantly reduced the rate of decline in forced vital capacity and delayed clinical worsening compared to placebo, with additional benefits observed in quality of life and other secondary endpoints. These findings support the use of inhaled treprostinil as a treatment option for IPF patients.

Metered-Dose Liquid Nitrogen Cryospray for Chronic Bronchitis: Results From the Prospective, Sham-Controlled Trial (SPRAY-CB)

Sep 22, 2026

The study aimed to evaluate the safety and effectiveness of metered cryospray (MCS) treatment using the RejuvenAir® System in patients with chronic bronchitis associated with COPD. Results showed that MCS treatment significantly improved quality of life measures (SGRQ and CAT scores) and reduced severe acute exacerbation rates compared to the control group, while maintaining an acceptable safety profile. Overall, the findings suggest that MCS may be a beneficial therapeutic option for this patient population.

Alveolar Ventilation Efficiency Assessed via Capnography is Associated with Improved Outcomes in Pediatric Cardiac Arrest

Sep 21, 2026

The authors aimed to quantitatively describe the airway opening index (AOI) during pediatric cardiopulmonary resuscitation (CPR) and evaluate its association with survival outcomes. They found that an AOI of 0.35 or higher was linked to improved survival to hospital discharge and better neurological outcomes, suggesting that higher AOI values indicate more effective ventilation during CPR. Additionally, events with higher AOI demonstrated improved post-arrest physiology, as evidenced by lower peak arterial lactate levels.

Defining disease stability in COPD: Evidence from Phase 3 clinical trials

Jun 12, 2026

The authors aimed to characterize disease stability in chronic obstructive pulmonary disease (COPD) as a composite endpoint and assess its prognostic value for long-term outcomes. Their analyses from multiple Phase 3 clinical trials indicated that achieving stability—defined as no moderate/severe exacerbations and no worsening in symptoms—was associated with significant reductions in the risk of exacerbations and all-cause mortality. The findings support the notion of disease stability as a viable treatment target in COPD, with implications for improving patient outcomes.

Association of White Blood Cell Count with Treatment Response to Cefepime vs Piperacillin-Tazobactam

Jun 11, 2026

The authors aimed to investigate whether white blood cell (WBC) count influences the relationship between antibiotic choice (cefepime vs. piperacillin-tazobactam) and mortality in sepsis treatment. Their analysis of data from the ACORN trial and an Instrumental Variable study revealed that WBC count significantly modified the effect of antibiotic choice on 28-day mortality, suggesting that higher baseline WBC counts were associated with better outcomes when treated with piperacillin-tazobactam. The findings indicate a need for further research to explore the potential of WBC count as a predictive marker in future studies of anti-pseudomonal antibiotics.

Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement

Jun 11, 2026

The authors aimed to develop a likelihood score to distinguish patients with pulmonary arterial hypertension (PAH) who have features of venous or capillary involvement (PVOD/PCH) from those with other forms of PAH. By analyzing clinical variables from existing literature, they created a score that demonstrated high accuracy in identifying PVOD/PCH, which could improve early diagnosis, management, and expedite lung transplant referrals for affected patients.